{"DataElement":{"publicId":"2675085","version":"6","preferredName":"Acute Lymphoblastic Leukemia Classification Type","preferredDefinition":"A description of acute lymphoblastic leukemia classification.","longName":"2674125v2.00:2672726v3.10","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2674125","version":"2","preferredName":"Acute Lymphoblastic Leukemia Classification","preferredDefinition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood.  It includes the precursor B lymphoblastic leukemia and precursor T lymphoblastic leukemia._A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.","longName":"ALL_CLASS","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2674126","version":"1","preferredName":"ALL","preferredDefinition":"A leukemia with an acute onset, characterized by the presence of lymphoblasts or Burkitt cells in the bone marrow and the peripheral blood.  It includes the precursor B lymphoblastic leukemia, precursor T lymphoblastic leukemia, and Burkitt's leukemia.","longName":"C3167","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Lymphoblastic Leukemia","conceptCode":"C3167","definition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3834F55C-324A-1EBE-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-21","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-08-21","modifiedBy":"ONEDATA","dateModified":"2007-08-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2321361","version":"1","preferredName":"Classification","preferredDefinition":"Classification; the grouping of things into classes or categories.","longName":"C25161","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Classification","conceptCode":"C25161","definition":"A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCF89106-20AF-2D93-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-29","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-07-29","modifiedBy":"ONEDATA","dateModified":"2005-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E2F9B8C8-5FD9-D64C-E040-BB89AD432D31","latestVersionIndicator":"Yes","beginDate":"2013-08-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-08-02","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2672726","version":"3.1","preferredName":"ALL Type","preferredDefinition":"A leukemia with an acute onset, characterized by the presence of lymphoblasts or Burkitt cells in the bone marrow and the peripheral blood.  It includes the precursor B lymphoblastic leukemia, precursor T lymphoblastic leukemia, and Burkitt's leukemia._Something distinguishable as an identifiable class based on common qualities.","longName":"2672726v3.10","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"B-lymphoblastic leukemia / lymphoma, not otherwise specified","valueDescription":null,"ValueMeaning":{"publicId":"5574401","version":"1","preferredName":"Blastic Plasmacytoid Dendritic Cell Neoplasm","longName":"5574401v1.00","preferredDefinition":"A clinically aggressive neoplasm derived from the precursors of plasmacytoid dendritic cells (also called professional type I interferon-producing cells or plasmacytoid monocytes), with a high frequency of cutaneous and bone marrow involvement and leukemic dissemination. (WHO 2017)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Blastic Plasmacytoid Dendritic Cell Neoplasm","conceptCode":"C7203","definition":"A clinically aggressive neoplasm derived from the precursors of plasmacytoid dendritic cells (also called professional type I interferon-producing cells or plasmacytoid monocytes), with a high frequency of cutaneous and bone marrow involvement and leukemic dissemination. (WHO 2017)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"41457D3D-7694-5F06-E053-F662850A638F","latestVersionIndicator":"Yes","beginDate":"2016-11-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-11-14","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F12E748-2943-3E47-E063-731AD00AA4FF","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"B-lymphoblastic leukemia / lymphoma with high hyperdiploidy","valueDescription":null,"ValueMeaning":{"publicId":"5574403","version":"1","preferredName":"B Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy","longName":"5574403","preferredDefinition":"A precursor lymphoid neoplasm composed of B-lymphoblasts which contain more than 50 and usually less than 66 chromosomes. It has a favorable clinical outcome.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hyperdiploid B Lymphoblastic Leukemia/Lymphoma","conceptCode":"C80335","definition":"A precursor lymphoid neoplasm composed of B-lymphoblasts which contain more than 50 and usually less than 66 chromosomes. It has a favorable clinical outcome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"41457D3D-76BA-5F06-E053-F662850A638F","latestVersionIndicator":"Yes","beginDate":"2016-11-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-11-14","modifiedBy":"KUMMEROA","dateModified":"2022-11-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F12E748-2944-3E47-E063-731AD00AA4FF","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"B-lymphoblastic leukemia / lymphoma with hypodiploidy","valueDescription":null,"ValueMeaning":{"publicId":"5574405","version":"1","preferredName":"B Lymphoblastic Leukemia/Lymphoma with Hypodiploidy","longName":"5574405","preferredDefinition":"A precursor lymphoid neoplasm composed of B-lymphoblasts which contain less than 46 chromosomes. It has an unfavorable clinical outcome.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hypodiploid B Lymphoblastic Leukemia/Lymphoma","conceptCode":"C80338","definition":"A precursor lymphoid neoplasm composed of B-lymphoblasts which contain less than 46 chromosomes. It has an unfavorable clinical outcome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"41457D3D-76E0-5F06-E053-F662850A638F","latestVersionIndicator":"Yes","beginDate":"2016-11-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-11-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F12E748-2945-3E47-E063-731AD00AA4FF","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"B-lymphoblastic leukemia / lymphoma, with iAMP21","valueDescription":null,"ValueMeaning":{"publicId":"14679027","version":"1","preferredName":"B Lymphoblastic Leukemia/Lymphoma with Intrachromosomal Amplification of Chromosome 21","longName":"14679027v1.00","preferredDefinition":"B lymphoblastic leukemia/lymphoma characterized by amplification of a portion of chromosome 21. It usually occurs in children and is associated with an adverse prognosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"B Lymphoblastic Leukemia/Lymphoma with Intrachromosomal Amplification of Chromosome 21","conceptCode":"C130039","definition":"B lymphoblastic leukemia/lymphoma characterized by amplification of a portion of chromosome 21. It usually occurs in children and is associated with an adverse prognosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F12E748-2938-3E47-E063-731AD00AA4FF","latestVersionIndicator":"Yes","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F12E748-2946-3E47-E063-731AD00AA4FF","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"B-lymphoblastic leukemia / lymphoma with BCR::ABL1 fusion","valueDescription":null,"ValueMeaning":{"publicId":"5574409","version":"1","preferredName":"B Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1","longName":"5574409","preferredDefinition":"A precursor lymphoid neoplasm which is composed of B-lymphoblasts and carries a translocation between the BCR gene on chromosome 22 and the ABL1 gene on chromosome 9. It results in the production of the p190 kd or p210 kd fusion protein. It has an unfavorable clinical outcome.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"B Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1","conceptCode":"C80331","definition":"A precursor lymphoid neoplasm which is composed of B-lymphoblasts and carries a translocation between the BCR gene on chromosome 22 and the ABL1 gene on chromosome 9. It results in the production of the p190 kd or p210 kd fusion protein. It has an unfavorable clinical outcome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"41457D3D-7740-5F06-E053-F662850A638F","latestVersionIndicator":"Yes","beginDate":"2016-11-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-11-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Updated VM Long Name_ghd_11.16.16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F12E748-2947-3E47-E063-731AD00AA4FF","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"B-lymphoblastic leukemia / lymphoma, BCR::ABL1-like features","valueDescription":null,"ValueMeaning":{"publicId":"5578251","version":"1","preferredName":"B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like","longName":"5578251","preferredDefinition":"B lymphoblastic leukemia/lymphoma with translocations involving tyrosine kinases, or translocations involving either the cytokine receptor-like factor 2 (CRLF2) or rearrangements leading to truncation and activation of the erythropoietin receptor (EPOR). It is associated with an adverse prognosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like","conceptCode":"C129787","definition":"B lymphoblastic leukemia/lymphoma characterized by a gene-expression profile similar to that of BCR-ABL1-positive B lymphoblastic leukemia/lymphoma, absence of the pathognomonic BCR-ABL1 rearrangement, alterations of lymphoid transcription factor genes, and a poor outcome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"41817DF1-B35B-6EFE-E053-F662850A0613","latestVersionIndicator":"Yes","beginDate":"2016-11-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-11-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F12E748-2948-3E47-E063-731AD00AA4FF","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"B-lymphoblastic leukemia / lymphoma with KMT2A rearrangement","valueDescription":null,"ValueMeaning":{"publicId":"5574411","version":"1","preferredName":"B Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A Rearranged","longName":"5574411","preferredDefinition":"A precursor lymphoid neoplasm which is composed of B-lymphoblasts and carries a translocation between the KMT2A gene at 11q23.3 and another gene partner resulting in the production of a KMT2A related fusion protein.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"B Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A Rearranged","conceptCode":"C80332","definition":"A precursor lymphoid neoplasm which is composed of B-lymphoblasts and carries a translocation between the KMT2A gene at 11q23.3 and another gene partner resulting in the production of an KMT2A related fusion protein.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"41457D3D-7766-5F06-E053-F662850A638F","latestVersionIndicator":"Yes","beginDate":"2016-11-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-11-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Updated definition and VM Long Name_ghd_11.16.16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F12E748-2949-3E47-E063-731AD00AA4FF","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"B-lymphoblastic leukemia / lymphoma with ETV6::RUNX1 fusion","valueDescription":null,"ValueMeaning":{"publicId":"5574407","version":"1","preferredName":"B Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1","longName":"5574407","preferredDefinition":"A precursor lymphoid neoplasm which is composed of B-lymphoblasts and carries a translocation between the TEL gene on chromosome 12 and the AML1 gene on chromosome 21, (p13.2;q22.1). It results in the production of the TEL-AML1 (ETV6-RUNX1) fusion protein. It has a favorable clinical outcome.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"B Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1","conceptCode":"C80334","definition":"A precursor lymphoid neoplasm which is composed of B-lymphoblasts and carries a translocation between the TEL gene on chromosome 12 and the AML1 gene on chromosome 21, (p13.2;q22.1). It results in the production of the TEL-AML1 (ETV6-RUNX1) fusion protein. It has a favorable clinical outcome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"41457D3D-7706-5F06-E053-F662850A638F","latestVersionIndicator":"Yes","beginDate":"2016-11-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-11-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Updated definition and VM Long Name_ghd_11.16.16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F12E748-294A-3E47-E063-731AD00AA4FF","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"B-lymphoblastic leukemia / lymphoma with ETV6::RUNX1-like features","valueDescription":null,"ValueMeaning":{"publicId":"14679028","version":"1","preferredName":"B Lymphoblastic Leukemia/Lymphoma with ETV6-RUNX1-Like Features","longName":"14679028v1.00","preferredDefinition":"B lymphoblastic leukemia/lymphoma characterized by a gene-expression profile similar to that of ETV6-RUNX1-positive B lymphoblastic leukemia/lymphoma, absence of the pathognomonic ETV6-RUNX1 rearrangement, and rearrangements or deletions of ETV6 and IKZF1 genes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"B Lymphoblastic Leukemia/Lymphoma with ETV6-RUNX1-Like Features","conceptCode":"C190956","definition":"B lymphoblastic leukemia/lymphoma characterized by a gene-expression profile similar to that of ETV6-RUNX1-positive B lymphoblastic leukemia/lymphoma, absence of the pathognomonic ETV6-RUNX1 rearrangement, and rearrangements or deletions of ETV6 and IKZF1 genes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F12E748-2939-3E47-E063-731AD00AA4FF","latestVersionIndicator":"Yes","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F12E748-294B-3E47-E063-731AD00AA4FF","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"B-lymphoblastic leukemia / lymphoma with TCF3::PBX1 fusion","valueDescription":null,"ValueMeaning":{"publicId":"5589065","version":"1","preferredName":"B Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1)","longName":"5589065","preferredDefinition":"A precursor lymphoid neoplasm which is composed of B-lymphoblasts and carries a translocation between the E2A gene on chromosome 19 and the PBX1 gene on chromosome 1.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"B Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1","conceptCode":"C80341","definition":"A precursor lymphoid neoplasm which is composed of B-lymphoblasts and carries a translocation between the E2A gene on chromosome 19 and the PBX1 gene on chromosome 1.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42B3B596-6A5E-73CB-E053-F662850A292D","latestVersionIndicator":"Yes","beginDate":"2016-12-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-12-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F12E748-294C-3E47-E063-731AD00AA4FF","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"B-lymphoblastic leukemia / lymphoma with IGH::IL3 fusion","valueDescription":null,"ValueMeaning":{"publicId":"3935832","version":"1","preferredName":"B Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.3); IL3-IGH","longName":"3935832","preferredDefinition":"A precursor lymphoid neoplasm which is composed of B-lymphoblasts and carries a translocation between the IL3 gene on chromosome 5 and the IGH locus on chromosome 14, (q31.1;q32.3). It results in eosinophilia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"B Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.3); IL3-IGH","conceptCode":"C80340","definition":"A precursor lymphoid neoplasm which is composed of B-lymphoblasts and carries a translocation between the IL3 gene on chromosome 5 and the IGH locus on chromosome 14, (q31.1;q32.3). It results in eosinophilia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9E0CCBC-2953-32FB-E040-BB89AD43176B","latestVersionIndicator":"Yes","beginDate":"2013-10-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-29","modifiedBy":"KUMMEROA","dateModified":"2022-11-28","changeDescription":"Updated definition and VM Long Name_ghd_11.16.16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F12E748-294D-3E47-E063-731AD00AA4FF","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"B-lymphoblastic leukemia / lymphoma with TCF3::HLF fusion","valueDescription":null,"ValueMeaning":{"publicId":"14679029","version":"1","preferredName":"B Lymphoblastic Leukemia/Lymphoma with TCF3-HLF Rearrangement","longName":"14679029v1.00","preferredDefinition":"An exceptionally rare childhood B-lymphoblastic leukemia/lymphoma associated with TCF3-HLF gene rearrangement resulting in the formation of TCF3-HLF chimeric transcription factor. The prognosis is poor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"B Lymphoblastic Leukemia/Lymphoma with TCF3-HLF Rearrangement","conceptCode":"C200587","definition":"An exceptionally rare childhood B-lymphoblastic leukemia/lymphoma associated with TCF3-HLF gene rearrangement resulting in the formation of TCF3-HLF chimeric transcription factor. The prognosis is poor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F12E748-293A-3E47-E063-731AD00AA4FF","latestVersionIndicator":"Yes","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F12E748-294E-3E47-E063-731AD00AA4FF","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"B-lymphoblastic leukemia / lymphoma with DUX4 rearrangement","valueDescription":null,"ValueMeaning":{"publicId":"14679030","version":"1","preferredName":"B Acute Lymphoblastic Leukemia with DUX4 Rearrangement","longName":"14679030v1.00","preferredDefinition":"B-acute lymphoblastic leukemia associated with DUX4 gene rearrangement. The prognosis is good.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"B Acute Lymphoblastic Leukemia with DUX4 Rearrangement","conceptCode":"C199232","definition":"B-acute lymphoblastic leukemia associated with DUX4 gene rearrangement. The prognosis is good.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F12E748-293B-3E47-E063-731AD00AA4FF","latestVersionIndicator":"Yes","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F12E748-294F-3E47-E063-731AD00AA4FF","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"B-lymphoblastic leukemia / lymphoma with IG::MYC fusion","valueDescription":null,"ValueMeaning":{"publicId":"14679031","version":"1","preferredName":"B Lymphoblastic Leukemia/Lymphoma with MYC Rearrangement","longName":"14679031v1.00","preferredDefinition":"B-lymphoblastic leukemia/lymphoma associated with MYC gene rearrangement. The prognosis is poor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"B Lymphoblastic Leukemia/Lymphoma with MYC Rearrangement","conceptCode":"C199231","definition":"B-lymphoblastic leukemia/lymphoma associated with MYC gene rearrangement. The prognosis is poor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F12E748-293C-3E47-E063-731AD00AA4FF","latestVersionIndicator":"Yes","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F12E748-2950-3E47-E063-731AD00AA4FF","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"B-lymphoblastic leukemia / lymphoma with MEF2D rearrangement","valueDescription":null,"ValueMeaning":{"publicId":"14679032","version":"1","preferredName":"B Acute Lymphoblastic Leukemia with MEF2D Rearrangement","longName":"14679032v1.00","preferredDefinition":"B-acute lymphoblastic leukemia associated with MEF2D gene rearrangement. The prognosis is poor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"B Acute Lymphoblastic Leukemia with MEF2D Rearrangement","conceptCode":"C199233","definition":"B-acute lymphoblastic leukemia associated with MEF2D gene rearrangement. The prognosis is poor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F12E748-293D-3E47-E063-731AD00AA4FF","latestVersionIndicator":"Yes","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F12E748-2951-3E47-E063-731AD00AA4FF","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"B-lymphoblastic leukemia / lymphoma with ZNF384 rearrangement","valueDescription":null,"ValueMeaning":{"publicId":"14679033","version":"1","preferredName":"Acute Leukemia of Ambiguous Lineage with BCL11B Rearrangement","longName":"14679033v1.00","preferredDefinition":"A rare acute leukemia of ambiguous lineage characterized by the presence of BCL11B gene rearrangement.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Leukemia of Ambiguous Lineage with BCL11B Rearrangement","conceptCode":"C203437","definition":"A rare acute leukemia of ambiguous lineage characterized by the presence of BCL11B gene rearrangement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F12E748-293E-3E47-E063-731AD00AA4FF","latestVersionIndicator":"Yes","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F12E748-2952-3E47-E063-731AD00AA4FF","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"B-lymphoblastic leukemia / lymphoma with NUTM1 rearrangement","valueDescription":null,"ValueMeaning":{"publicId":"14679034","version":"1","preferredName":"B Acute Lymphoblastic Leukemia with NUTM1 Rearrangement","longName":"14679034v1.00","preferredDefinition":"B-acute lymphoblastic leukemia associated with NUTM1 gene rearrangement. The prognosis is good.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"B Acute Lymphoblastic Leukemia with NUTM1 Rearrangement","conceptCode":"C199239","definition":"B-acute lymphoblastic leukemia associated with NUTM1 gene rearrangement. The prognosis is good.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F12E748-293F-3E47-E063-731AD00AA4FF","latestVersionIndicator":"Yes","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F12E748-2953-3E47-E063-731AD00AA4FF","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"B-lymphoblastic leukemia / lymphoma with PAX5 p.P80R abnormalities","valueDescription":null,"ValueMeaning":{"publicId":"14679035","version":"1","preferredName":"B Acute Lymphoblastic Leukemia with PAX5 P80R Mutation","longName":"14679035v1.00","preferredDefinition":"B-acute lymphoblastic leukemia associated with PAX5 P80R mutation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"B Acute Lymphoblastic Leukemia with PAX5 P80R Mutation","conceptCode":"C199260","definition":"B-acute lymphoblastic leukemia associated with PAX5 P80R mutation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F12E748-2940-3E47-E063-731AD00AA4FF","latestVersionIndicator":"Yes","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F12E748-2954-3E47-E063-731AD00AA4FF","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"T-lymphoblastic leukemia / lymphoma","valueDescription":null,"ValueMeaning":{"publicId":"2568286","version":"1","preferredName":"Precursor T-lymphoblastic lymphoma/leukemia","longName":"2568286v1.00","preferredDefinition":"A neoplasm of lymphoblasts committed to the T-cell lineage, typically composed of small to medium-sized blast cells.  When the neoplasm involves predominantly the bone marrow and the peripheral blood, it is called T acute lymphoblastic leukemia.  When it involves nodal or extranodal sites it is called T lymphoblastic lymphoma. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T Lymphoblastic Leukemia/Lymphoma","conceptCode":"C8694","definition":"A neoplasm of lymphoblasts committed to the T-cell lineage, typically composed of small to medium-sized blast cells.  When the neoplasm involves predominantly the bone marrow and the peripheral blood, it is called T acute lymphoblastic leukemia.  When it involves nodal or extranodal sites it is called T lymphoblastic lymphoma. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D7CB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-30","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-30","modifiedBy":"KUMMEROA","dateModified":"2022-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F12E748-2955-3E47-E063-731AD00AA4FF","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"Early T-precursor lymphoblastic leukemia / lymphoma","valueDescription":null,"ValueMeaning":{"publicId":"14679036","version":"1","preferredName":"Early T Precursor Lymphoblastic Leukemia/Lymphoma","longName":"14679036v1.00","preferredDefinition":"T lymphoblastic leukemia/lymphoma in which the blasts have unique immunophenotypic and genetic characteristics suggesting only limited early T-cell differentiation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Early T Precursor Lymphoblastic Leukemia/Lymphoma","conceptCode":"C199170","definition":"T lymphoblastic leukemia/lymphoma in which the blasts have unique immunophenotypic and genetic characteristics suggesting only limited early T-cell differentiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F12E748-2941-3E47-E063-731AD00AA4FF","latestVersionIndicator":"Yes","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F12E748-2956-3E47-E063-731AD00AA4FF","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"Early T-precursor lymphoblastic leukemia / lymphoma, with BCL11B","valueDescription":null,"ValueMeaning":{"publicId":"14679037","version":"1","preferredName":"Early T Precursor Acute Lymphoblastic Leukemia with BCL11B Rearrangement","longName":"14679037v1.00","preferredDefinition":"Early T precursor acute lymphoblastic leukemia associated with the presence of BCL11B gene rearrangement.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Early T Precursor Acute Lymphoblastic Leukemia with BCL11B Rearrangement","conceptCode":"C199171","definition":"An early T precursor acute lymphoblastic leukemia associated with the presence of BCL11B gene rearrangement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F12E748-2942-3E47-E063-731AD00AA4FF","latestVersionIndicator":"Yes","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F12E748-2957-3E47-E063-731AD00AA4FF","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"Natural killer (NK)- cell lymphoblastic leukemia / lymphoma","valueDescription":null,"ValueMeaning":{"publicId":"5574523","version":"1","preferredName":"Natural Killer Cell Lymphoblastic Leukemia/Lymphoma","longName":"5574523","preferredDefinition":"A provisional entity describing precursor lymphoid neoplasms that express CD56 and immature T-cell markers, lack B-lymphoid and myeloid markers, and have the immunoglobulin and T-cell receptor genes in the germline configuration.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Natural Killer Cell Lymphoblastic Leukemia/Lymphoma","conceptCode":"C82217","definition":"A precursor lymphoid neoplasm that expresses CD56 and immature T-cell markers, lacks B-lymphoid and myeloid markers, and has immunoglobulin and T-cell receptor genes in the germline configuration.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"41473745-456E-3570-E053-F662850A84CC","latestVersionIndicator":"Yes","beginDate":"2016-11-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-11-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F12E748-2958-3E47-E063-731AD00AA4FF","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"B-lymphoblastic leukemia / lymphoma with PAX5alt abnormalities","valueDescription":null,"ValueMeaning":{"publicId":"14679039","version":"1","preferredName":"B Acute Lymphoblastic Leukemia with PAX5 Alteration","longName":"14679039v1.00","preferredDefinition":"B-acute lymphoblastic leukemia associated with PAX5 gene alteration, including rearrangements, point mutations, and intragenic lesions. This is a provisional entity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"B Acute Lymphoblastic Leukemia with PAX5 Alteration","conceptCode":"C199264","definition":"B-acute lymphoblastic leukemia associated with PAX5 gene alteration, including rearrangements, point mutations, and intragenic lesions. This is a provisional entity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F13128F-6E2E-4610-E063-731AD00A4497","latestVersionIndicator":"Yes","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F13128F-6E2F-4610-E063-731AD00A4497","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2486814","version":"1","preferredName":"ALL Type","preferredDefinition":"A leukemia with an acute onset, characterized by the presence of lymphoblasts or Burkitt cells in the bone marrow and the peripheral blood.  It includes the precursor B lymphoblastic leukemia, precursor T lymphoblastic leukemia, and Burkitt's leukemia.:Type; a subdivision of a particular kind of thing.","longName":"C3167:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Lymphoblastic Leukemia","conceptCode":"C3167","definition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"16358911-6390-2575-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-14","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-14","modifiedBy":"ONEDATA","dateModified":"2006-06-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"DRAFT MOD","registrationStatus":"Application","id":"0F12C271-3C34-3489-E063-731AD00AA94B","latestVersionIndicator":"Yes","beginDate":"2019-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","changeDescription":". Versioned to correct PVs on 2402r4. Added 2 PVs for Duke. AK 2020-5-7","administrativeNotes":"2024.1.6 Created newer version to reflect disease name updates. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2695319","version":"1","longName":"NMDP: CDEs to review","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"2964924","version":"1","longName":"2400r1: Pre-TED","context":"NHLBI"}]},{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"pre_ted_who_all","type":"NMDP_FN","context":"NHLBI"},{"name":"Precursor Lymphoblastic Leukemia Classification Type","type":"System-Generated","context":"NHLBI"},{"name":"PreTed_prime_dis_hct_all_class","type":"NMDP_FN","context":"NHLBI"},{"name":"TDIS_ALL_all_class","type":"NMDP_FN","context":"NHLBI"},{"name":"CPRE_ICT_all_class","type":"NMDP_FN","context":"NHLBI"},{"name":"PerformedDiagnosis:value","type":"HCT_BRIDG","context":"NHLBI"},{"name":"DCI","type":"USED_BY","context":"DCI"}],"ReferenceDocuments":[{"name":"PQT","type":"Preferred Question Text","description":"Specify the type of acute lymphoblastic leukemia:","url":null,"context":"NHLBI"},{"name":"BRIDG mapping path for CDE:2675085","type":"BRIDG Mapping Path","description":"PerformedDiagnosis [major classification] > AssessedResultRelationship > PerformedObservation > PerformedDiagnosis.value(ANY=>CD).code [detailed classification] WHERE PerformedDiagnosis.value(ANY=>CD).code [major classification] = \"Acute Lymphoblastic Leukemia(ALL)\"","url":null,"context":"NHLBI"},{"name":"Specify ALL classification","type":"Alternate Question Text","description":"Specify ALL classification","url":null,"context":"NHLBI"},{"name":"Specify ALL classification","type":"Application Standard Question Text","description":"Specify ALL classification","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"DRAFT MOD","registrationStatus":"Application","id":"0F1322F9-85E8-48EE-E063-731AD00A6612","latestVersionIndicator":"Yes","beginDate":"2019-01-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","changeDescription":". System generated def displayed as alt def.; System generated def displayed as alt def.","administrativeNotes":"20024.1.16 Created per ticket request CADSR0003263. ak","unresolvedIssues":null,"deletedIndicator":"No"}}